Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05976334 | An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 3 | TakedaINDUSTRY | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07207681 | Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT04215978 | Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 204 | BeiGeneINDUSTRY | 8 | Oct 3, 2025 | clinicaltrials |
| NCT04631029 | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06260774 | Study of TTX-MC138 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 16 | TransCode TherapeuticsINDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT03993873 | Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET(SHIELD-1) | active not recruiting | Phase 1 | 95 | Turning Point Therapeutics, Inc.INDUSTRY | 5 | Oct 1, 2025 | clinicaltrials |
| NCT06126666 | A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 96 | ABL Bio, Inc.INDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06296056 | Phase I Trial of Combined Immune Cell Therapy for Metastatic Stage IV Solid Tumors (SDH-Combi)(SDH-Combi) | completed | Phase 1 | 9 | Seoul HospitalOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06933524 | Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors(ATB-320-001A) | not yet recruiting | Phase 1 | 24 | AutotelicbioINDUSTRY | 0 | Oct 1, 2025 | clinicaltrials |
| NCT03493945 | Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) | completed | Phase 1 / Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07196579 | Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04606472 | A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 60 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05385692 | A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors | active not recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05803018 | A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies | recruiting | Phase 1 / Phase 2 | 38 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06241898 | A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 300 | Bliss Biopharmaceutical (Hangzhou) Co., LtdINDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT03191682 | A First-in-Human Study of PRL3-ZUMAB | active not recruiting | Phase 1 | 38 | National University Hospital, SingaporeOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04710043 | Dose Escalation Trial of BNT152+153 in Patients With Cancer | completed | Phase 1 | 86 | BioNTech SEINDUSTRY | 2 | Sep 25, 2025 | clinicaltrials |
| NCT05821777 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 25 | Centessa Pharmaceuticals (UK) LimitedINDUSTRY | 2 | Sep 25, 2025 | clinicaltrials |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 23 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04674748 | To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550 | terminated | Phase 1 | 3 | Incyte Biosciences Japan GKINDUSTRY | 1 | Sep 24, 2025 | clinicaltrials |
| NCT05163028 | A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | active not recruiting | Phase 1 | 42 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT05485974 | A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation | active not recruiting | Phase 1 | 44 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT05841563 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | recruiting | Phase 1 | 125 | PharmaMarINDUSTRY | 3 | Sep 24, 2025 | clinicaltrials |
| NCT05941507 | A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 300 | LigaChem Biosciences, Inc.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT06212076 | Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients | recruiting | Phase 1 / Phase 2 | 60 | Nanjing Immunophage Biotech Co., LtdINDUSTRY | 1 | Sep 24, 2025 | clinicaltrials |
| NCT05381038 | Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | recruiting | Phase 1 / Phase 2 | 10 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06520488 | A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 118 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 | clinicaltrials |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | terminated | Phase 1 | 75 | Ikena OncologyINDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06469008 | A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 21 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06475131 | A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 21 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06493864 | A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 21 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06500052 | A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06985355 | A Study of MHB046C Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04372641 | Testing the Safety of CB-5339 in Patients With Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05807035 | Autologous Tumour Vaccine Trial | recruiting | Phase 1 | 30 | Vaxine Pty LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06182579 | Phase I Study of RiMO-401 With Radiation in Advanced Tumors | terminated | Phase 1 | 5 | Coordination Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04064359 | Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors | recruiting | Phase 1 | 200 | Oxford BioTherapeutics LtdINDUSTRY | 5 | Sep 16, 2025 | clinicaltrials |
| NCT04242147 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors | terminated | Phase 1 | 45 | Kadmon, a Sanofi CompanyINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05072106 | Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors | completed | Phase 1 | 11 | PharmaMarINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05109832 | A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects | completed | Phase 1 | 6 | Impact Therapeutics, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05390944 | An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition | completed | Phase 1 | 28 | Impact Therapeutics, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05391048 | An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition | completed | Phase 1 | 36 | Impact Therapeutics, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05904496 | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 44 | BeiGeneINDUSTRY | 4 | Sep 16, 2025 | clinicaltrials |
| NCT05989997 | Phase I Clinical Trial of 68Ga-NOTA-SNA002 | completed | Phase 1 | 17 | SmartNuclide BiopharmaINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT03195478 | A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 37 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03944499 | Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer. | completed | Phase 1 | 161 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04446260 | A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors | completed | Phase 1 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 5 | Sep 15, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Oct 6, 2025source: clinicaltrials